Kalaris Therapeutics Inc
KLRS10.060USD
+0.930+10.19%
收盤 12/22, 16:00（美東）報價延遲15分鐘
188.15M總市值
虧損本益比TTM
關於 Kalaris Therapeutics Inc 公司
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Kalaris Therapeutics Inc簡介
公司代碼KLRS
公司名稱Kalaris Therapeutics Inc
上市日期Jul 30, 2020
CEOOxtoby (Andrew)
員工數量6
證券類型Ordinary Share
年結日Jul 30
公司地址400 Connell Drive
城市BERKELEY HEIGHTS
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編07922
電話16502492727
網址https://kalaristx.com/
公司代碼KLRS
上市日期Jul 30, 2020
CEOOxtoby (Andrew)
Kalaris Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Napoleone Ferrara, M.D.
Dr. Napoleone Ferrara, M.D.
Director
Director
504.00K
--
Mr. David L. Hallal
Mr. David L. Hallal
Executive Chairman of the Board
Executive Chairman of the Board
130.55K
+1.18%
Dr. Matthew Feinsod, M.D.
Dr. Matthew Feinsod, M.D.
Chief Medical Officer
Chief Medical Officer
4.03K
--
Mr. Andrew Oxtoby
Mr. Andrew Oxtoby
Chief Executive Officer, Principal Executive Officer, Director
Chief Executive Officer, Principal Executive Officer, Director
--
--
Dr. Morana Jovan-Embiricos, Ph.D.
Dr. Morana Jovan-Embiricos, Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Director
Director
--
--
Dr. Anthony P. Adamis, M.D.
Dr. Anthony P. Adamis, M.D.
Director
Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Director
Director
--
--
Mr. Brett R. Hagen
Mr. Brett R. Hagen
Chief Accounting Officer
Chief Accounting Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Napoleone Ferrara, M.D.
Dr. Napoleone Ferrara, M.D.
Director
Director
504.00K
--
Mr. David L. Hallal
Mr. David L. Hallal
Executive Chairman of the Board
Executive Chairman of the Board
130.55K
+1.18%
Dr. Matthew Feinsod, M.D.
Dr. Matthew Feinsod, M.D.
Chief Medical Officer
Chief Medical Officer
4.03K
--
Mr. Andrew Oxtoby
Mr. Andrew Oxtoby
Chief Executive Officer, Principal Executive Officer, Director
Chief Executive Officer, Principal Executive Officer, Director
--
--
Dr. Morana Jovan-Embiricos, Ph.D.
Dr. Morana Jovan-Embiricos, Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
收入明細
FY2021
FY2020
FY2019
由於公司未披露，未能獲取相關數據
地區USD
名稱
營收
佔比
United States
0.00
0.00%
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Samsara BioCapital, LLC
61.21%
ElevateBio LLC
3.88%
Ferrara (Napoleone)
2.69%
F2 MG Ltd
2.28%
Tang Capital Management, LLC
2.24%
其他
27.70%
持股股東
持股股東
佔比
Samsara BioCapital, LLC
61.21%
ElevateBio LLC
3.88%
Ferrara (Napoleone)
2.69%
F2 MG Ltd
2.28%
Tang Capital Management, LLC
2.24%
其他
27.70%
股東類型
持股股東
佔比
Venture Capital
61.21%
Individual Investor
6.43%
Corporation
6.16%
Hedge Fund
4.35%
Investment Advisor
3.83%
Investment Advisor/Hedge Fund
1.42%
其他
16.59%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
193
13.23M
70.72%
-1.05M
2025Q2
227
16.58M
88.66%
+10.64M
2025Q1
234
16.39M
87.75%
+10.95M
2024Q4
237
3.88M
53.28%
-1.58M
2024Q3
243
4.43M
85.21%
-1.20M
2024Q2
253
4.51M
86.91%
-1.04M
2024Q1
252
4.61M
89.02%
-783.99K
2023Q4
254
4.25M
88.46%
-716.47K
2023Q3
253
4.79M
104.12%
+25.72K
2023Q2
259
4.80M
104.70%
+638.53K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Samsara BioCapital, LLC
11.45M
61.21%
--
--
Jun 30, 2025
ElevateBio LLC
724.99K
3.88%
--
--
Jun 25, 2025
Ferrara (Napoleone)
504.00K
2.69%
--
--
Jun 25, 2025
F2 MG Ltd
427.31K
2.28%
-1.00
-0.00%
Jun 25, 2025
Tang Capital Management, LLC
360.86K
1.93%
+51.64K
+16.70%
Jun 30, 2025
Invus Public Equities Advisors, LLC
282.59K
1.51%
--
--
Jun 30, 2025
Patel (Samirbhai Chandrakant)
252.00K
1.35%
+252.00K
--
Mar 18, 2025
Rezai (Kourous)
203.67K
1.09%
+203.67K
--
Jun 25, 2025
The Vanguard Group, Inc.
129.84K
0.69%
+14.75K
+12.82%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Value ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Equity ETF
0%
Proshares Ultra Russell 2000
0%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
Schwab U.S. Broad Market ETF
0%
ProShares UltraPro Russell2000
0%
查看更多
iShares Micro-Cap ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0%
Fidelity Enhanced Small Cap ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
Avantis US Equity ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Schwab U.S. Broad Market ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jan 10, 2025
Merger
23→1
公告日期
類型
比率
Jan 10, 2025
Merger
23→1
常見問題
Kalaris Therapeutics Inc的前五大股東是誰？
Kalaris Therapeutics Inc的前五大股東如下：
Samsara BioCapital, LLC持有股份：11.45M佔總股份比例：61.21%。
ElevateBio LLC持有股份：724.99K佔總股份比例：3.88%。
Ferrara (Napoleone)持有股份：504.00K佔總股份比例：2.69%。
F2 MG Ltd持有股份：427.31K佔總股份比例：2.28%。
Tang Capital Management, LLC持有股份：360.86K佔總股份比例：1.93%。
Samsara BioCapital, LLC持有股份：11.45M佔總股份比例：61.21%。
ElevateBio LLC持有股份：724.99K佔總股份比例：3.88%。
Ferrara (Napoleone)持有股份：504.00K佔總股份比例：2.69%。
F2 MG Ltd持有股份：427.31K佔總股份比例：2.28%。
Tang Capital Management, LLC持有股份：360.86K佔總股份比例：1.93%。
Kalaris Therapeutics Inc的前三大股東類型是什麼？
Kalaris Therapeutics Inc 的前三大股東類型分別是：
Samsara BioCapital, LLC
ElevateBio LLC
Ferrara (Napoleone)
Samsara BioCapital, LLC
ElevateBio LLC
Ferrara (Napoleone)
有多少機構持有Kalaris Therapeutics Inc(KLRS)的股份？
截至2025Q3，共有193家機構持有Kalaris Therapeutics Inc的股份，合計持有的股份價值約為13.23M，占公司總股份的70.72% 。與2025Q2相比，機構持股有所增加，增幅為-17.94%。
哪個業務部門對Kalaris Therapeutics Inc的收入貢獻最大？
在FY2021，--業務部門對Kalaris Therapeutics Inc的收入貢獻最大，創收--，占總收入的--% 。
